MMDA-02 TITLE:CLINICOPATHOLOGICAL CHARACTERISTICS OF PATIENTS WITH BRAIN METASTASES FROM LUNG ADENOCARCINOMA WITH MUTATED EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) IN THE RADIOTHERAPY DEPARTMENT OF THE NATIONAL ONCOLOGY INSTITUTE. YEARS 2018–2022
Neuro-Oncology Advances · 01.08.2026 · 8 (Supplement_6)
DOI: 10.1093/noajnl/vdag161.033 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuro-Oncology Advances, online erschienen am 07.08.2026. Verfasst von Rafael Arauz und 1 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
EGFR mutations are present in 32.4% of patients with lung adenocarcinoma (LUAD). Brain metastases (BM) from EGFR-mutated LUAD represent a major therapeutic challenge and remain a leading cause of death despite multidisciplinary treatment. Osimertinib crosses the blood-brain barrier and may improve intracranial disease control. This study aimed to determine the clinicopathological characteristics of patients with BM from LUAD with and without EGFR mutations treated with whole-brain radiotherapy (WBRT), with or without osimertinib.
Methods
A retrospective study was conducted at the National Cancer Institute from 2018 to 2022, including 79 symptomatic patients with BM who received WBRT. Patients were divided into two groups: EGFR-mutated (EGFR-m; n = 28) and EGFR non-mutated (EGFR-nm; n = 51). Clinical, therapeutic, and survival variables were analyzed using Chi-square/Fisher’s exact tests and Kaplan-Meier survival analysis.
Results
Mean age was 61.2±14.2 years in EGFR-m patients and 66.4±10.1 years in EGFR-nm patients (p = 0.05). Overall, 54.4% were women, with female sex predominating in EGFR-m patients (p = 0.006). Karnofsky performance status was ≤70 in 45.6% of cases. Non-smokers were more frequent in EGFR-m patients (p < 0.005). In the EGFR-m group, the mean number of BM lesions was 3.6±2.6 (range, 1-10; p = 0.56), and 91% had extracranial disease (p = 0.06). EGFR variants included exon 19 (64%), exon 20 (11%), and exon 21 (25%). WBRT dose was 20 Gy in 58.2% and ≥30 Gy in 41.8%. Among EGFR-m patients, 68% received osimertinib before, during, or after WBRT. Median overall survival was 4.1 months (95% CI, 2.1-6.0). Survival was longer in EGFR-m patients than in EGFR-nm patients: 7.2 versus 3.1 months (log-rank p = 0.045). Osimertinib exposure was associated with improved survival: 14.8 versus 2.7 months (p < 0.05).
Conclusion
Patients with EGFR-mutated LUAD and BM were younger, predominantly female, more often non-smokers, and mainly harbored exon 19 mutations. Survival was higher in patients treated with WBRT plus osimertinib.
Zitieren
APA
Arauz, R., & Barrera, W. (2026). MMDA-02 TITLE:CLINICOPATHOLOGICAL CHARACTERISTICS OF PATIENTS WITH BRAIN METASTASES FROM LUNG ADENOCARCINOMA WITH MUTATED EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) IN THE RADIOTHERAPY DEPARTMENT OF THE NATIONAL ONCOLOGY INSTITUTE. YEARS 2018–2022. Neuro-Oncology Advances, 8(Supplement_6). https://doi.org/10.1093/noajnl/vdag161.033
Vancouver
Arauz R, Barrera W. MMDA-02 TITLE:CLINICOPATHOLOGICAL CHARACTERISTICS OF PATIENTS WITH BRAIN METASTASES FROM LUNG ADENOCARCINOMA WITH MUTATED EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) IN THE RADIOTHERAPY DEPARTMENT OF THE NATIONAL ONCOLOGY INSTITUTE. YEARS 2018–2022. Neuro-Oncology Advances. 2026;8(Supplement_6). doi:10.1093/noajnl/vdag161.033
BibTeX
@article{Arauz2026,
author = {Arauz, Rafael and Barrera, Wilson},
title = {MMDA-02 TITLE:CLINICOPATHOLOGICAL CHARACTERISTICS OF PATIENTS WITH BRAIN METASTASES FROM LUNG ADENOCARCINOMA WITH MUTATED EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) IN THE RADIOTHERAPY DEPARTMENT OF THE NATIONAL ONCOLOGY INSTITUTE. YEARS 2018–2022},
journal = {Neuro-Oncology Advances},
year = {2026},
volume = {8},
number = {Supplement_6},
doi = {10.1093/noajnl/vdag161.033}
}
EUVIMED